Lara McGrath
Company: AstraZeneca
Job title: Director - Translational Medicine
Seminars:
Exploring the Design & Preclinical Activity of AZD9592: a Bispecific EGFRMET Targeted ADC 4:00 pm
Characterization of internalization and cytotoxic properties of AZD9592, a bispecific ADC designed to selectively bind EGFR and c-MET on tumor cells and deliver a topoisomerase 1 inhibitor payload Using in vivo PDX studies to explore relationship of target expression to tumor growth inhibition Pharmacodynamic biomarkers supporting multi-faceted mechanism of actionRead more
day: Conference Day One PM
Chair’s Opening Remarks 8:50 am
day: Conference Day One AM